328 related articles for article (PubMed ID: 35113805)
1. Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial.
Ajjan RA; Hensor EMA; Del Galdo F; Shams K; Abbas A; Fairclough RJ; Webber L; Pegg L; Freeman A; Taylor AE; Arlt W; Morgan AW; Tahrani AA; Stewart PM; Russell DA; Tiganescu A
Eur J Endocrinol; 2022 Feb; 186(4):441-455. PubMed ID: 35113805
[TBL] [Abstract][Full Text] [Related]
2. Effect of AZD4017, a Selective 11β-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia.
Abbas A; Schini M; Ainsworth G; Brown SR; Oughton J; Crowley RK; Cooper MS; Fairclough RJ; Eastell R; Stewart PM
J Clin Endocrinol Metab; 2022 Jun; 107(7):2026-2035. PubMed ID: 35275196
[TBL] [Abstract][Full Text] [Related]
3. 11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension.
Hardy RS; Botfield H; Markey K; Mitchell JL; Alimajstorovic Z; Westgate CSJ; Sagmeister M; Fairclough RJ; Ottridge RS; Yiangou A; Storbeck KH; Taylor AE; Gilligan LC; Arlt W; Stewart PM; Tomlinson JW; Mollan SP; Lavery GG; Sinclair AJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):174-187. PubMed ID: 33098644
[TBL] [Abstract][Full Text] [Related]
4. Topical 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Corrects Cutaneous Features of Systemic Glucocorticoid Excess in Female Mice.
Tiganescu A; Hupe M; Uchida Y; Mauro T; Elias PM; Holleran WM
Endocrinology; 2018 Jan; 159(1):547-556. PubMed ID: 29087473
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of 11β-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study.
Yadav Y; Dunagan K; Khot R; Venkatesh SK; Port J; Galderisi A; Cobelli C; Wegner C; Basu A; Carter R; Basu R
Diabetes Obes Metab; 2022 May; 24(5):881-890. PubMed ID: 35014156
[TBL] [Abstract][Full Text] [Related]
6. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial.
Markey K; Mitchell J; Botfield H; Ottridge RS; Matthews T; Krishnan A; Woolley R; Westgate C; Yiangou A; Alimajstorovic Z; Shah P; Rick C; Ives N; Taylor AE; Gilligan LC; Jenkinson C; Arlt W; Scotton W; Fairclough RJ; Singhal R; Stewart PM; Tomlinson JW; Lavery GG; Mollan SP; Sinclair AJ
Brain Commun; 2020; 2(1):fcz050. PubMed ID: 32954315
[TBL] [Abstract][Full Text] [Related]
7. 11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects.
Tiganescu A; Tahrani AA; Morgan SA; Otranto M; Desmoulière A; Abrahams L; Hassan-Smith Z; Walker EA; Rabbitt EH; Cooper MS; Amrein K; Lavery GG; Stewart PM
J Clin Invest; 2013 Jul; 123(7):3051-60. PubMed ID: 23722901
[TBL] [Abstract][Full Text] [Related]
8. 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.
Othonos N; Pofi R; Arvaniti A; White S; Bonaventura I; Nikolaou N; Moolla A; Marjot T; Stimson RH; van Beek AP; van Faassen M; Isidori AM; Bateman E; Sadler R; Karpe F; Stewart PM; Webster C; Duffy J; Eastell R; Gossiel F; Cornfield T; Hodson L; Jane Escott K; Whittaker A; Kirik U; Coleman RL; Scott CAB; Milton JE; Agbaje O; Holman RR; Tomlinson JW
Nat Commun; 2023 Feb; 14(1):1025. PubMed ID: 36823106
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017).
Scott JS; Bowker SS; Deschoolmeester J; Gerhardt S; Hargreaves D; Kilgour E; Lloyd A; Mayers RM; McCoull W; Newcombe NJ; Ogg D; Packer MJ; Rees A; Revill J; Schofield P; Selmi N; Swales JG; Whittamore PR
J Med Chem; 2012 Jun; 55(12):5951-64. PubMed ID: 22691057
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of 11β-HSD1 Expression by Insulin in Skin: Impact for Diabetic Wound Healing.
Brazel CB; Simon JC; Tuckermann JP; Saalbach A
J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33260645
[TBL] [Abstract][Full Text] [Related]
12. Increased glucocorticoid activation during mouse skin wound healing.
Tiganescu A; Hupe M; Uchida Y; Mauro T; Elias PM; Holleran WM
J Endocrinol; 2014 Apr; 221(1):51-61. PubMed ID: 24464022
[TBL] [Abstract][Full Text] [Related]
13. NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial.
Balingit PP; Armstrong DG; Reyzelman AM; Bolton L; Verco SJ; Rodgers KE; Nigh KA; diZerega GS
Wound Repair Regen; 2012; 20(4):482-90. PubMed ID: 22672145
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial.
Markey KA; Ottridge R; Mitchell JL; Rick C; Woolley R; Ives N; Nightingale P; Sinclair AJ
JMIR Res Protoc; 2017 Sep; 6(9):e181. PubMed ID: 28923789
[TBL] [Abstract][Full Text] [Related]
15. Automated quantification of 3D wound morphology by machine learning and optical coherence tomography in type 2 diabetes.
Wang Y; Freeman A; Ajjan R; Del Galdo F; Tiganescu A
Skin Health Dis; 2023 Jun; 3(3):e203. PubMed ID: 37275432
[TBL] [Abstract][Full Text] [Related]
16. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
[TBL] [Abstract][Full Text] [Related]
17. Identification of a human blood biomarker of pharmacological 11β-hydroxysteroid dehydrogenase 1 inhibition.
Gómez C; Alimajstorovic Z; Othonos N; Winter DV; White S; Lavery GG; Tomlinson JW; Sinclair AJ; Odermatt A
Br J Pharmacol; 2024 Mar; 181(5):698-711. PubMed ID: 37740611
[TBL] [Abstract][Full Text] [Related]
18. 11β-Hydroxysteroid dehydrogenase-1 is a novel regulator of skin homeostasis and a candidate target for promoting tissue repair.
Terao M; Murota H; Kimura A; Kato A; Ishikawa A; Igawa K; Miyoshi E; Katayama I
PLoS One; 2011; 6(9):e25039. PubMed ID: 21949844
[TBL] [Abstract][Full Text] [Related]
19. Role of corticosteroids in skin physiology and therapeutic potential of an 11β-HSD1 inhibitor: A review.
Hall L; Hart R
Int J Dermatol; 2024 Apr; 63(4):443-454. PubMed ID: 38146184
[TBL] [Abstract][Full Text] [Related]
20. Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes.
Jang C; Obeyesekere VR; Dilley RJ; Krozowski Z; Inder WJ; Alford FP
J Clin Endocrinol Metab; 2007 Aug; 92(8):3314-20. PubMed ID: 17519316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
